Choose Language
Select a language for news translation.
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechn…
Written by Andy Gould for The Motley Fool -> The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the …
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Bio…
Written by Brendan Coffey for The Motley Fool -> State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared t…
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through …
(RTTNews) - Synlogic, Inc. (SYBX), a biotechnology company, on Wednesday entered into a definitive merger agreement with Caldera Therapeutics, Inc. in an all-s…
The US is making measles great again, so treatment options are needed for the most vulnerable.
Vanguard’s VHT offers lower fees and double the dividend yield of Invesco’s IBBQ through broader healthcare exposure. This makes VHT a cost-effective choice fo…
Written by Eric Volkman for The Motley Fool -> He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about t…
Written by Prosper Junior Bakiny for The Motley Fool -> Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. …
